Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.
Authors
Shi-xue Laoguo
The First Affiliated Hospital of Guangxi Medical University, Nanning, China;
Shi-xue Laoguo , Huasheng Huang , Jie Zeng , Yangfeng Jiang , Cuizhen Liu , Ning Mo , GuangZhi Zhu , Fuchao Ma , Tao Peng , Zhiming Zeng , Jie Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 576)
DOI
10.1200/JCO.2023.41.4_suppl.576
Abstract #
576
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma.
First Author: Haifeng Lin
Poster
2021 Gastrointestinal Cancers Symposium
Preliminary results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma.
First Author: Haifeng Lin
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
First Author: Yongkang Xu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.
First Author: Gong-Rang Chen